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Original Report 
Seroprevalence and risk factors for human T-cell 
lymphotropic virus (HTLV-I) infection among ethnically 
and geographically diverse Peruvian women 
C. Sanchez-Palacios,(i) E. Gotuzzo,(2) A.-M. Vandammec3) and Y. Maldonado(4) 
Objective: To assess the seroprevalence and risk factors for HTLV-I infection in Peruvian women. 
Methods: Five hundred and sixty-eight healthy women ~20 years of age from three Peruvian regions were randomly 
selected and screened for HTLV-I. ELISA-reactive sera were confirmed via immunofluorescence assay, recombinant 
immunoblot assay, Western blot, and PCR. Women from Huanta (n=303), an Andean city inhabited by indigenous 
Quechuans, El Carmen (n=132), a primarily African-American coastal town, and Lima (n=133), with its Mestizo 
population, were selected. 
Results: HTLV-I antibodies were present in 2.5% (14/568) of women (1.3% in Huanta, 3.8% in El Carmen, and 3.8% 
in Lima); 2.5%, 2.7% and 2.6% of Quechuans, Mestizas and African-Americans, respectively, were infected. History 
of a blood transfusion (P<O.O0002), chronic scabies (P<O.O2), having a relative with leukemia (P<O.O4), age &38 
years (P<O.O3), young age at first intercourse (PcO.04) lifetime partners >4 (P<O.O4), educational status (PcO.02) 
and >4 pregnancies (PcO.03) were significantly associated with infection. 
Conclusions: HTLV-I is endemic among asymptomatic Peruvian women. Parenteral, vertical and heterosexual 
transmission are associated with infection. 
Int J Infect Dis 2003; 7: 132-137 
INTRODUCTION 
The human T-cell lymphotrophic viruses (HTLV) are 
associated with two main clinical entities: adult T-cell 
leukemia/lymphoma (ATLL), and HTLV-I-associated 
myelopathy (HAM) or tropical spastic paraparesis 
(TSP).1,2 HTLV is endemic in Japan, the Carribbean, 
equatorial Africa, Latin America, north-eastern Iran, 
Melanesia, and the Solomon Islands, and among 
Australian Aborigines. 3-6 The highest prevalence rates 
for HTLV-I have been documented in south-western 
Japan (17%) and in the Caribbean basin (4-9%); in the 
USA, the rate is 0.016-0.1%.7-10 HTLV-I has infected 
an estimated lo-20 million individuals worldwide, but 
precise figures are not available.ll 
HTLV-I is highly cell-associated, and requires the 
passage of infected lymphocytes to noninfected indi- 
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viduals, whereas HIV can be transmitted extracellular- 
ly.s,12 HTLV-I is transmitted through sexual intercourse, 
whole blood, or cellular blood products, and vertically 
from mother to child, postnatally via breastfeeding.13-l6 
Currently, there is a lack of evidence for intrauterine or 
perinatal infection with HTLV-I.14,17-22 
People of African origin have a higher prevalence of 
HTLV-I than other populations in the same hyper- 
endemic regions of comparable socioeconomic status.23,24 
A preferential geographic focus in the Andes for HTLV- 
I infection has been suggested by various studies.23,25 
The transmission mechanisms in HTLV-I infection are 
incompletely understood, since: (1) HTLV-I is found 
almost exclusively in tropical areas of the world; 
(2) there is evidence for both familial and neighborhood 
clustering among cases;26 and (3) in people migrating 
from endemic to non-endemic areas, HTLV-I seroposi- 
tivity declines in subsequent generations. Japanese people 
infected by HTLV-I have a higher rate of ATLL (4% 
cumulative lifetime risk) and a lower rate of TSP (0.25%) 
when compared to infected people from the Caribbean 
with cumulative lifetime risks calculated at 1% and 2%, 
respective1y.l’ The mechanisms that determine HTLV-I 
pathogenesis are currently unknown.27 
Based on a cohort study conducted in Miyasaki, 
Japan, the seroprevalence curve for HTLV-I demon- 
strates a parallel increase in seropositivity for men and 
women until age 55 (at 25%) followed by a plateauing 
effect among men and a continued increase among 
women (to 52%). 28,29 Similar results have been reported 
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in other studies.24,30 HTLV-I infection was also associated 
with low socioeconomic status, lack of education, and 
the practice of prostitution, among other factors.23,30-32 
The objective of this study was to investigate HTLV- 
I infection in Peru among healthy, asymptomatic women 
more than 20 years of age who did not practice high-risk 
behaviors for acquiring HTLV-I infection. Second, we 
assessed whether HTLV-I infection rate varied with geo- 
graphic and/or ethnic diversity. Third, we assessed risk 
factors that predispose to HTLV-I infection. 
MATERIALS AND METHODS 
This study was conducted in three regions of Peru: 
Huanta, El Carmen, and Lima. The Andean city of 
Huanta is located at an altitude of 2400 m, and is 
inhabited by an indigenous Quechuan population 
(26 741 inhabitants). El Carmen is a Pacific coastal town 
located 200 km south of the capital city of Lima, and is 
inhabited predominantly by an African-American 
population (total population 10 980). Lima is the capital 
of Peru; it is located on the Pacific coast, and is inhabited 
by 7 million people. The majority of the population is 
considered to be ‘Mestizo’, a mix of Spanish and 
indigenous Indian blood. The ‘North Cone’, the neigh- 
borhood where this study was conducted, is inhabited by 
a Mestizo population of low socioeconomic status. 
Based on our sample sizes and village population 
sizes, we were able to detect with 99% accuracy a true 
population prevalence of at least 2-5 %. Based on census 
data calculations, 4.3% (n=303) of women >20 years of 
age were sampled in Huanta, and 5.6% (n=132) of 
women >20 years of age were sampled in El Carmen. 
Since Huanta and El Carmen are divided into census 
squares, each census square was selected in a blinded 
fashion, and women were enrolled into the study via 
a household visit. Random sampling was ensured by 
indiscriminately selecting women from different census 
tracts. In Lima, healthy women from the ‘North Cone’ 
>20 years of age who brought their children for routine 
immunizations to the Cayetano Heredia Hospital were 
enrolled. 
Human subjects approval was obtained from 
Stanford University and Cayetano Heredia University. 
The purposes of our study were explained, and those 
women who provided written or oral (for the illiterate) 
informed consent were enrolled. A detailed question- 
naire was orally administered in Spanish or Quechua, 
recording demographic information and possible risk 
factors for HTLV-I infection. A blood sample (8 mL) 
was obtained and processed daily, and serum was stored 
at -70°C until being transported to the laboratory at 
the Instituto de Medicina Tropical Alexander Von 
Humboldt (IMT AVH) in Lima to be assayed. 
The presence of HTLV-I antibodies was assessed by 
an enzyme-linked immunosorbent assay (ELISA, Platelia 
HTLV-I New) (Sanofi Diagnostics Pasteur, Paris, France) 
and repeated if positive. Persistently reactive sera under- 
went confirmatory testing by immunofluorescence assay 
(IFA) (R. M. Hendry, California Department of Health 
Services, Berkeley, CA, USA), HTLV I/II recombinant 
immunoblot assay (RIBA, Chiron Corporation, 
Emeryville, CA, USA), Western blot (WB, Cambridge 
Biotech, Worcester, MA, USA), and polymerase chain 
reaction (PCR, Belgium, A. M. Vandamme). In our 
study, serum samples were defined as HTLV-I positive if 
ELISA results were concordant with the four 
confirmatory methods used (IFA, RIBA, WB, and PCR). 
Epi Info 6.04b software was used to analyze our 
data and perform chi-square and Fisher’s exact test. P- 
values co.05 were considered to be statistically signi- 
ficant. 
RESULTS 
In total, 568 women were enrolled in this study. Table 1 
shows the demographic characteristics of the subjects 
studied: 23.2% (n=132) were from El Carmen (African- 
American), 53.3% (n=303) from Huanta (indigenous), 
and 23.4% (n=133) from Lima (Mestizo). The ages 
ranged between 20 and 82 years. The racial distribution 
of the volunteers included 34.8% (n=198) Quechuans, 
46.5% (n=264) Mestizas, 13.4% (n=76) African- 
American, and 5.3 % (n = 30) Mestizo-African- American. 
Of the total enrolled, 38.9% (n=220) were born on 
the coast, 59.4% (n=337) in the Andes, and only 1.8% 
(n=lO) in the jungle area. 
HTLV-I antibodies were demonstrated in 2.5% 
(14 of 568) of asymptomatic women from El Carmen, 
Huanta, and Lima. No cases with HTLV-II infection 
were detected in this study. 
Assessment of HTLV-I seropositivity per geographic 
location yielded the following results: 3.8% (5 of 132) 
for El Carmen, 1.3% (4 of 303) for Huanta, and 3.8% (5 
of 133) for Lima. These differences were non-significant. 
Seropositivity for HTLV-I increased with age, but this 
increase was found to be non-significant. According to 
birthplace (Table l), 2.1% of those born in the Andes 
were HTLV-I-infected compared to 3.2% of those born 
in the coastal region and 0% of those born in the jungle. 
The rates of HTLV-I infection according to ethnicity 
were 2.5% (5 of 198) in the Quechuans, 2.7% (7 of 264) 
in Mestizos, 2.6% (2/76) in African-Americans, and 0% 
(0 of 30) in the Mestizo-African-American population; 
these differences were found to be non-significant. 
Among the subjects from El Carmen who had at 
least one Andean parent, 25% (3 of 12) were infected 
compared to 0.4% of those who did not have an Andean 
parent (OR 19.7, P<O.O05). In Lima, this factor was 
found to be non-significant. 
Factors that were significantly associated with 
HTLV-I infection in our study were the following (Table 
2): history of a blood transfusion (P<O.O0002, OR 13.1), 
having had an episode of chronic scabies (PcO.02, OR 
13.0), having had a relative with leukemia or lymphoma 
(PcO.04, OR 4.8), age at first intercourse less than or 
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Table 1. Demographic characteristics and HTLV-I seropositivity 
according to geographic location, ethnicity, age, and birthplace 
(n=568) 
NumberlTotal HTLV-I 
(%) positive (%) 
Geographic El Carmen 1321568 (23.2) 5/l 32 (3.8) 
location Huanta 303/568 (53.3) 4/303 (1.3) 
Lima 133/568 (23.4) 5/l 33 (3.8) 
Ethnicity Quechua 1981568 (34.8) 5/l 98 (2.5) 
Mestizo 264/568 (46.5) 71264 (2.7) 
African-American 76/568 (13.4) 2176 (2.6) 
Mestizo/African 30/568 (5.3) o/30 (0.0) 
Age 20-30 years 131/564 (23.2) 2/131 (1.5) 
3 I-40 years 2661564 (47.2) 6/266 (2.3) 
41-50 years 94/564 (16.7) 3/94 (3.2) 
> 50 years 73/564 (12.9) 3173 (4.1) 
Place of Coast 220/567 (38.9) 7/220 (3.2) 
birth Andes 337/567 (59.4) 7/337 (2.1) 
Jungle 1 O/567 (1.8) O/l 0 (0.0) 
equal to 20 years (mean age of first intercourse=19.7 
years) (PcO.04, OR 6.4), age equal to or greater than 38 
years (PcO.03, OR 3.8), and number of sexual partners 
in life greater than four (PcO.04, OR 8.2). The popu- 
lation studied was primarily monogamous (66%). There 
was only one female sex worker (FSW) in our study, and 
she was found to be uninfected with HTLV-I. 
Socioeconomic factors significantly associated with 
HTLV-I infection included education status and multi- 
parity. Of the women who had studied for 7 or years or 
less (53.2% or 302/568), 4.0% (12 of 302) were found to 
be infected, compared to 0.8% (2 of 266) of those who 
had studied for more than 7 years (PcO.02, OR 5.5).The 
mean number of pregnancies was 4.2. Of the women 
who had been pregnant more than four times (37.1% or 
211/568), 4.3% (9 of 211) were infected, compared to 
1.4% (5 of 357) of those who had been pregnant four or 
less times (PcO.03, OR 3.1). Lack of a sewer system, 
living in a home without electric light or potable water, 
or never having used birth control, were associated 
with a higher percentage of infection, although these 
differences were non-significant. In this study, 59.9% 
of women had either never used birth control or were 
using the rhythm method as their contraception of 
choice; 33.6% were using contraceptive methods not 
protective against sexual transmission of HTLV-I, in- 
eluding injections, intrauterine devices (IUDs), tubal 
ligation, and oral contraceptives. Only 6.5% (n=37) were 
using or had used condoms. 
No significant association was demonstrated between 
HTLV-I infection and frequent use of intramuscular 
injections, having undergone a surgical procedure or 
Caesarean section, having had a history of hepatitis or 
jaundice, a parasitic infection, or a sexually transmitted 
disease (STD), or having been breastfed for longer than 
6 months or 1 year. Although the presence of these risk 
factors was associated with a higher rate of infection, 
these differences were found to be non-significant. Only 
3.7% of women studied reported an STD history. A 
history of genital ulcer was reported by 5.5%, having 
had a partner with an STD by 1.5%, and having had a 
partner with a genital ulcer by 2.2%; however, none of 
these women was HTLV-I-infected. 
DISCUSSION 
There have been reports of high HTLV-I infection rates 
in South America;33-3s however, this is the largest study 
conducted in Peru among asymptomatic women from 
three different ethnic groups and geographic regions. 
Our study complements a recent study in Quillabamba, 
Peru, an Andean region, which found HTLV-I infection 
rates of 2.3% in healthy pregnant women (n=211), 
13.7% in FSWs, and 8.5% in STD patients.40 In our 
study, a seropositivity rate of 2.5% (14 of 568) was found 
among women studied. Specifically, infection rates were 
3.8% for El Carmen and Lima, and 1.3% for Huanta 
(Andes). These rates are significant, and confirm the fact 
that HTLV-I infection is an important public health 
problem in Peru. HTLV-I infection occurs not only 
among high-risk groups (i.e. FSWs, STD carriers), but 
also in healthy, asymptomatic women. HTLV-I infection 
rates in Peru are similar to those found in other endemic 
areas of the world, but not as high as in Okinawa (15%). 
Sonoda et al have described two mutually exclusive 
HLA haplotypes associated with HTLV infection, sug- 
gesting that distinct haplotypes could determine suscepti- 
bility patterns to infection by HTLV-I or HTLV-I14r 
The first haplotype was found among South American 
Andes natives and Japanese with exclusive infection by 
HTLV-I, while the second was found among Orinoco 
Table 2. Factors associated with human T-cell lymphotrophic virus type-l (HTLV-I) infection among healthy, asymptomatic women in 
Peru (n=568) 
HTLV-I positive/Total (x) 
Factor Yes No Odds ratio (Cl) P-value 
Blood transfusion 
Severe resistant scabies 
Relative with leukemia/lymphoma 
Age at first intercourse ~20 years 
Number of sexual partners in life >4 
Age 238 years 
Years of education ~7 
Pregnant >4 times 
8/59 (13.6) 
2/9 (22.2) 
3/32 (9.4) 
13/385 (3.4) 
2/13 (15.4) 
101229 (4.4) 
12/302 (4.0) 
g/211 (4.3) 
6/506 (1.2) 
121557 (0.2) 
1 l/519 (2.1) 
l/183 (0.5) 
12/555 (2.1) 
4/339 (1.2) 
2/266 (0.8) 
5/357 (1.4) 
13.1 (3.9-45.0) 
13.0 (1.6-82.0) 
4.8 (1.02-20.2) 
6.4 (1.1-133.5) 
8.2 (1.1-37.7) 
3.8 (1.1-14.8) 
5.5 (1.1-36.1) 
3.1 (1.0-I 1 .O) 
P<0.00002 
P40.02 
PCO.04 
PCO.04 
PCO.04 
PCO.03 
P<O.OZ 
PCO.03 
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natives in the lowlands of South America and North 
American Indians with exclusive infection by HTLV- 
II.41 In a second phylogenetic study of South American 
natives, HLA haplotypes among HTLV-I and HTLV-II 
carriers were found to be mutually segregated, repre- 
senting genetic backgrounds that could account for differ- 
ing susceptibilities to HTLV42-43 This could explain the 
presence of segregated foci of HTLV-I infection in the 
Andes highlands among Quechuan natives and HTLV- 
II infection in the Orinoco lowlands of Colombia among 
the Guahibo Indians. Our study with the Quechuan popu- 
lation confirmed the exclusive presence of HTLV-I. 
Our study found a 2.6% infection rate among the 
African-American women surveyed. Gessain et al found 
virtually identical sequences between isolates from 
West Africa, the Ivory Coast and the Central African 
Republic and those from the French West Indies, Haiti, 
French Guyana and Peru. 44 One theory included an 
ancient introduction from mongoloid migrations.45-47 
The second hypothesis argues for a post-Columbian 
introduction of HTLV-I from Africa into the western 
hemisphere as a result of the slave trade about 350 years 
ago,44>45,48-50 and a more recent migration of HTLV-I- 
infected Japanese to America.5o 
Of the HTLV-I-infected subjects, 50% (7/14) had 
been born in the Andean region (35.7% in El Carmen 
and 14.3% in Lima). This correlates well with our initial 
findings that linked HTLV-I infection with birth in the 
Andean region. Among TSP patients in Lima, 48% 
had been born in the Andes, while 68% had lived a 
significant proportion of their lives in this same region.25 
In HTLV-I-associated Stvongyloides stercovalis-hyper- 
infected patients presenting in Lima, almost 50% were 
born in the Andes region. 51 In the coastal city of El 
Carmen, having at least a father or mother from the 
Andes was significantly associated with an increased 
HTLV-I infection rate (P<O.O05). The infection rate 
found in Lima (3.8%) in the ill mestizo population 
represents migration of Quechuans to the capital city, 
making a new endemic region. This study confirms that 
the Andean Valley is endemic for HTLV-I. 
History of a blood transfusion was significantly 
associated with HTLV-I infection, such that 13.6% of 
people who had received a blood transfusion were 
HTLV-I-infected (P<O.O0002), compared to 1.2% who 
had not. This is a plausible transmission route, con- 
sidering that, at the time of this study, blood in Peru was 
not being screened for anti-HTLV-I antibodies prior to 
transfusion. Japan, with its high prevalence of HTLV-I, 
as well as low-prevalence areas such as the USA and 
Europe, is currently screening for anti-HTLV-I/II 
antibodies.9,52z53 In other studies in Colombia and 
Martinique, involving healthy populations,23:27 blood 
transfusion was reported as a risk factor for infection 
with HTLV-I, as has been described in series of 
TSP/HAM patients.25,31T54,55 
Heterosexual transmission appears to be another 
route of HTLV-I transmission among the Peruvian 
women studied. This is supported by the fact that early 
age at first intercourse (120 years, P<O.O4), having 
more than four sexual partners in life (PcO.04) and 
multiparity (being pregnant >4 times, P<O.O3), were 
significantly associated with infection. Early age at first 
intercourse might imply a greater number of lifetime 
sexual partners as well as longer duration of relationship 
with the same seropositive partner, which have been 
found to be associated with increased risk of HTLV-I 
transmission.56 Furthermore, condoms were being used 
by only 6.5% (n=37) of the women surveyed.Also, IUD 
use has been associated with increased HTLV-I 
infection, and is considered to represent a high risk for 
retroviral infection, secondary to its association with 
pelvic infections and the fact that mucosal alterations 
and a high level of lymphocytic infiltration of the cervix 
or uterus occur with an IUD in place; 57~58 however, none 
of these patients was using an IUD. In addition, anatomic 
differences may increase the efficiency of male-to-female 
HTLV-I transmission.29,59 Many studies report STDs as 
being significantly associated with HTLV-I infection. In 
our study, only 3.7% of women reported having an STD. 
Being 38 years or more of age (mean age 38.6) was 
significantly associated with increased HTLV-I infection 
(PcO.03). In other series, the seropositivity increased 
with age, probably due to more risk and cumulative risk 
as a result of sexual exposure, or by the cohort effect. In 
different Peruvian studies, we have demonstrated that 
age is an important factor.30,40 
Having a relative with leukemia or lymphoma 
was a significant risk factor for HTLV-I infection (OR 
4.8, PcO.04). In our study, 9.4% of patients having a 
relative with leukemia or lymphoma were infected, 
compared to 2.1% of women without relatives with 
leukemia (P<O.O4). HLTV-I is associated with ATLL in 
Japan and Latin America.48 
HTLV-I has been associated with an immuno- 
suppressive state. 29,60-62 Crusted (Norwegian) scabies is 
a rare form of scabies that affects the immunosuppressed 
host. Some reports have associated crusted scabies and 
HTLV-I seropositivity. 63-67 One study found all patients 
with crusted scabies to be HTLV-I positive.68 In our 
study, a significant correlation between HTLV-I infection 
and severe resistant scabies was found (PcO.02). 
Besides the known endemicity of HTLV-I in Japan, 
Africa, and the Caribbean, this study confirms that 
HLTV-I infection is endemic in Peru and is an important 
public health problem, currently under-recognized. 
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